Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Holo-TC study results could boost B12 assay market

This article was originally published in Clinica

Executive Summary

Axis-Shield (Dundee, UK) has restated its belief that its Holo-TC assay for the biologically active part of the vitamin B12 molecule could replace serum B12 as a standard marker for Alzheimer's disease. The statement follows the completion of a joint study between the Universities of Oxford (UK) and Bergen (Norway), which confirmed that low serum levels of Holo-TC are associated with the disease.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT072075

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel